HIGHLIGHTS
- who: Sandra Gonzau0301lez Fernau0301ndez and colleagues from the (UNIVERSITY) have published the research: Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin, in the Journal: Journal of Oncology 5 of 12/08/2022
- what: The aim of this study was to evaluate the safety overall and progression-free survival clinical response and quality of life in adult patients with inoperable esophageal tumors of epithelial origin treated with nimotuzumab in a practical context. The most frequent and related adverse events (diarrhea, chills, and tremors) that appeared in this study have been reported in previous . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.